Bibliography
- HOLLOPETER G, JANTZEN H, VINCENT D et al.: Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature (2001) 11:145-147.
- HASS WK, EASTON JD, ADAMS HP et al.: A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N. Engl. J. Med. (1989) 321:501-507.
- SUGIDACHI A, ASAI F, YONEDA K et al.: Antiplatelet action of R-99224, an active metabolite of a novel thienopyridine-type GI-linked P2T antagonist, CS-747. Br. J. Pharmacol. (2001) 132:47-54.
- SOLET D, ZACHARSKI L, PLEHN J: The role of adenosine 5′-diphosphate receptor blockade in patients with cardiovascular disease. Am. J. Med. (2001) 111:45-53.
- MULLER I et al.: Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart (2001) 85:92-93
- WEBER A, BRAUN M, HOHLFELD T: Recovery of platelet function after discontinuation of clopidogrel in healthy volunteers. Br. J. Clin. Pharmacol. (2001) 52:333-336.
- BATES ER et al.: Drud–drug interactions involving antiplateletagents. Eu. Heart J. (2003) 24:1707-1709.
- Lau WC et al.: Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation (2004) 109:166-171.
- SAUCEDO JF, AUDE W, GARZA L: Statin therapy with atorvastatin or simvastatin does not decrease the antiplatelet effect of clopidogrel or eptifibatide during percutaneous intervention. Circulation (2003) 108(Suppl. IV):IV-579. (Abstract 2637).
- MILLER I, BESTA F, SCHULZ C et al.: Effects of statins on platelet inhibition by a high loading dose of clopidogrel. Circulation (2003) 108:2195-2197.
- SEREBRUANY VL, MIDEI MG, MALININ AI et al.: Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study. Arch. Intern. Med. (2004) 164:2051-2057.
- CAPRIE STEERING COMMITTEE: A randomized, blinded,trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet (1996) 348:1329-1339.
- THE CURE INVESTIGATORS: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndrome without ST segment elevation. N. Engl. J. Med. (2001) 345:494-502.
- FOX KA, MEHTA SR, PETERS R et al.: Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation (2004) 110:1202-1208.
- SABATINE M, CANNON C, GIBSON M et al.; FOR THE CLARITY-TIMI 28 INVESTIGATORS: Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST segment elevation. N. Engl. J. Med. (2005) 352:1179-1189.
- CHEN ZM, XIANG LX, CHEN YP: Addition of clopidogrel to aspirin in 45852 patients with acute myocardial infarction: randomized placebo-controlled trial. Lancet (2005) 366:1607-1621.
- MEHTA SR, YUSUF S, PETERS RJG et al.: Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet (2001) 358:527-533.
- SABATINE MS, CANNON CP, GIBSON CM et al.: Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics. The PCI-CLARITY study. JAMA (2005) 294:1224-1232.
- STEINHUBL SR, BERGER PB, MANN 3RD JT et al.: Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA (2002) 288:2411-2420.
- HEESCHEN C et al.: For the PRISM Study investigators. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. Lancet (1999) 354:1757-1762.
- PRISM-PLUS STUDY: The platelet receptor inhibition in ischemic syndrome management in patients limited by unstable angina and symptoms study investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non Q wave myocardial infarction. N. Engl. J. Med. (1998) 338:1488-1497.
- WHITE H: Low molecular weight heparin and platelet glycoprotein IIb/IIIa receptor blockade in acute coronary syndromes: complementary or competing therapies. J. Invas. Cardiol. (2000) 12:A6-A13.
- BOERSMA E, HARRINGTON RA, MOLITERNO DJ et al.: Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomized clinical trials. Lancet (2002) 359:189-198.
- KASTRATI A, JULINDA M, NEUMANN F: Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment. The ISAR-REACT 2 trial. JAMA (2006) 296:1531-1538.
- STONE G, WHITE H, OHMAN E: Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet (2007) 369:907-919.
- BHATT DL, FOX KAA, HACKE W et al.; FOR THE CHARISMA INVESTIGATORS: Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N. Engl. J. Med. (2006) 354(16):1706-1717.
- BHATT DL, FLATHER MD, HACKE W et al.: Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J. Am. Coll. Cardiol. (2007) 49:1982-1988.
- WIVIOTT SD, ANTMAN EM, GIBSON CM: Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioNwith prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Am. Heart J. (2006) 152:627-635.
- WIVIOTT SD, ANTMAN EM, WINTERS KJ: Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention. Results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 Trial. Circulation (2005) 111:3366-3373.
- BEOHAR N, DAVIDSON CJ, KIP KE et al.: Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA (2007) 297:1992-2000.
- WIN HK, CALDERA AE, MARESH K et al.: Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA (2007) 297:2001-2009.
- HARRINGTON RA, OHMAN EM: The enigma of drug-eluting stents: hope, hype, humility, and advancing patient care. JAMA (2007) 297:2028-2030.
- HANKEY G, EIKELBOOM J: Aspirin resistance. BMJ (2004) 328:477-479.
- THE TASK FORCE FOR THE DIAGNOSIS AND MANAGEMENT OF NON ST ELEVATION ACUTE CORONARY SYNDROME FOR THE EUROPEAN SOCIETY OF CARDIOLOGY: Guideline for the diagnosis and management of non ST elevation acute coronary syndrome. Eur. Heart J. (2007) 28:1598-1660.
- NATIONAL COLLABORATING CENTRE FOR PRIMARY CARE: NICE clinical guideline 48 MI: secondary prevention (2007).
- FOX KA: Is clopidogrel plus aspirin more cost-effective than aspirin alone in high-risk patients with acute coronary syndromes? Nat. Clin. Pract. Cardiovasc. Med. (2005) 2:444-445.